期刊文献+

Adjuvant radiochemotherapy for gastric cancer:should weuse prognostic factors to select patients? 被引量:3

Adjuvant radiochemotherapy for gastric cancer: should we use prognostic factors to select patients?
下载PDF
导出
摘要 Radiotherapy has a not well-established role in the pre-operative and in the post-operative setting in gastric cancer(GC) patients. Randomized trials report controversial outcomes and impact on survival. In the D2 loco-regional node resection era, after a wellperformed radical surgery, local treatment using radiotherapy combined to chemotherapy should be considered for locally advanced GC. Prognostic factors could help the better selection of subgroups that present high risk of loco-regional recurrence. Then, the addition of radiotherapy could improve the diseasefree survival and also quality of life. There are no large prospective studies that have assessed specific factors predicting for recurrence or survival, but only retrospective series, some of them including high number of patients with homogeneous characteristics. In locally advanced GC adding radiotherapy to the postoperative chemotherapy seems to improve outcomes and quality of life. Prognostic factors such as T-stage, N-status, nodal ratio, and other histological factors should be considered to submit patients to postoperative combined treatment. Larger prospective series are necessary to investigate the role of combined chemoradiation after radical D2-resection, especially in locally advanced GC. Further prospective investigations are needed to suggest prognostic factors that have significant impact on survival and recurrence, improving the management and outcomes, particularly in locally advanced GC patients. Radiotherapy has a not well-established role in the pre-operative and in the post-operative setting in gastric cancer(GC) patients. Randomized trials report controversial outcomes and impact on survival. In the D2 loco-regional node resection era, after a wellperformed radical surgery, local treatment using radiotherapy combined to chemotherapy should be considered for locally advanced GC. Prognostic factors could help the better selection of subgroups that present high risk of loco-regional recurrence. Then, the addition of radiotherapy could improve the diseasefree survival and also quality of life. There are no large prospective studies that have assessed specific factors predicting for recurrence or survival, but only retrospective series, some of them including high number of patients with homogeneous characteristics. In locally advanced GC adding radiotherapy to the postoperative chemotherapy seems to improve outcomes and quality of life. Prognostic factors such as T-stage, N-status, nodal ratio, and other histological factors should be considered to submit patients to postoperative combined treatment. Larger prospective series are necessary to investigate the role of combined chemoradiation after radical D2-resection, especially in locally advanced GC. Further prospective investigations are needed to suggest prognostic factors that have significant impact on survival and recurrence, improving the management and outcomes, particularly in locally advanced GC patients.
机构地区 Radiation Oncology
出处 《World Journal of Gastroenterology》 SCIE CAS 2016年第3期1131-1138,共8页 世界胃肠病学杂志(英文版)
关键词 Gastric cancer ADJUVANT RADIOTHERAPY PROGNOSTIC factors LOCALLY advanced disease Selectedpatients Gastric cancer Adjuvant radiotherapy Prognostic factors Locally advanced disease Selected patients
  • 相关文献

参考文献49

  • 1Yao JC, Mansfield PF, Pisters PW, Feig BW, Janjan NA, Crane C,Ajani JA. Combined-modality therapy for gastric cancer. SeminSurg Oncol 2003; 21: 223-227 [PMID: 14648779].
  • 2Wang J, Sun Y, Bertagnolli MM. Comparison of gastric cancersurvival between Caucasian and Asian patients treated in theUnited States: results from the Surveillance Epidemiology and EndResults (SEER) database. Ann Surg Oncol 2015; 22: 2965-2971[PMID: 25631065 DOI: 10.1245/s10434-015-4388-4].
  • 3Allemani C, Weir HK, Carreira H, Harewood R, Spika D, WangXS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Azevedo e Silva G, Chen WQ, OgunbiyiOJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M,Storm H, Tucker TC, Coleman MP. Global surveillance of cancersurvival 1995-2009: analysis of individual data for 25,676,887patients from 279 population-based registries in 67 countries(CONCORD-2). Lancet 2015; 385: 977-1010 [PMID: 25467588DOI: 10.1016/S0140-6736(14)62038-9].
  • 4Gomez SL, Noone AM, Lichtensztajn DY, Scoppa S, GibsonJT, Liu L, Morris C, Kwong S, Fish K, Wilkens LR, GoodmanMT, Deapen D, Miller BA. Cancer incidence trends amongAsian American populations in the United States, 1990-2008. JNatl Cancer Inst 2013; 105: 1096-1110 [PMID: 23878350 DOI:10.1093/jnci/djt157].
  • 5Oh DY, Bang YJ. Adjuvant and neoadjuvant therapy for gastriccancer. Curr Treat Options Oncol 2013; 14: 311-320 [PMID:23686725 DOI: 10.1007/s11864-013-0238-4].
  • 6Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, EstesNC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL,Jessup JM, Martenson JA. Chemoradiotherapy after surgerycompared with surgery alone for adenocarcinoma of the stomachor gastroesophageal junction. N Engl J Med 2001; 345: 725-730[PMID: 11547741].
  • 7Lee J, Lim do H, Kim S, Park SH, Park JO, Park YS, Lim HY, ChoiMG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, ParkCK, Kim KM, Kang WK. Phase III trial comparing capecitabineplus cisplatin versus capecitabine plus cisplatin with concurrentcapecitabine radiotherapy in completely resected gastric cancer withD2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012;30: 268-273 [PMID: 22184384 DOI: 10.1200/JCO.2011.39.1953].
  • 8Cunningham D, Allum WH, Stenning SP, Thompson JN, Vande Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, IvesonTJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ.Perioperative chemotherapy versus surgery alone for resectablegastroesophageal cancer. N Engl J Med 2006; 355: 11-20 [PMID:16822992].
  • 9An JY, Cheong JH, Hyung WJ, Noh SH. Recent evolution ofsurgical treatment for gastric cancer in Korea. J Gastric Cancer2011; 11: 1-6 [PMID: 22076195 DOI: 10.5230/jgc.2011.11.1.1].
  • 10Lee JH, Kim KM, Cheong JH, Noh SH. Current management andfuture strategies of gastric cancer. Yonsei Med J 2012; 53: 248-257[PMID: 22318810 DOI: 10.3349/ymj.2012.53.2.248].

同被引文献17

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部